Apimeds Pharmaceuticals US

APUS · NYSE American

$3.41−$0.09 (−2.57%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $3.50

About APUS

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.

Employees: 2
Headquarters: Matawan, New Jersey
Listed: May 9, 2025
Sector: Health Care
Industry: Biotechnology
Website: apimedsus.com

Leadership

Apimeds Pharmaceuticals US executives
Name	Title	Since	Age
Erik Emerson	—	—	54
Vin Menon	—	2025	—
Erick Frim	—	—	67
Jakap Koo	—	—	64
Elona Kogan	—	—	55
Carol O'Donnell	—	—	68
Bennett Weintraub	—	—	56

Similar companies

Companies in the same industry as Apimeds Pharmaceuticals US

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.